Gilead, Merck Initiate Phase 2 Study of Oral Weekly HIV-1 Treatment Combo

  This Clinical Study is the First from Merck and Gilead’s Collaboration to Develop Potential Long-Acting HIV Treatment Options –

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.

https://finance.yahoo.com/news/gilead-merck-initiate-phase-2-104500626.html